Sven Zimmermann
Algemeen Directeur bij Inotrem SA
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Jean-Jacques Garaud | M | 69 |
Inotrem SA
 Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 11 jaar |
| Thierry Hercend | M | - |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Marc Derive | M | - |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 11 jaar |
| Bernard Mach | M | 90 |
MaxiVAX SA
 MaxiVAX SA Miscellaneous Commercial ServicesCommercial Services MaxiVAX SA is a Swiss clinical stage biotechnology company. The private company is based in Geneva, Switzerland. The company was founded by Bernard Mach. | 19 jaar |
| Luke Beshar | M | 65 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 3 jaar |
| T. Scott Johnson | M | 76 |
MaxiVAX SA
MaxiVAX SA Miscellaneous Commercial ServicesCommercial Services MaxiVAX SA is a Swiss clinical stage biotechnology company. The private company is based in Geneva, Switzerland. The company was founded by Bernard Mach. | - |
| Thomas Möller | M | 54 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| François Thomas | M | 66 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Hans Caspar von der Crone | M | 67 |
University of Zurich
| 27 jaar |
| Graziano Seghezzi | M | 55 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Gilles Nobécourt | M | 67 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Ena Prossner | M | 58 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 4 jaar |
| Martin Koch | M | 62 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 6 jaar |
| Ksenija Aranicki Pavletic | F | - |
MaxiVAX SA
MaxiVAX SA Miscellaneous Commercial ServicesCommercial Services MaxiVAX SA is a Swiss clinical stage biotechnology company. The private company is based in Geneva, Switzerland. The company was founded by Bernard Mach. | - |
| Jason Robert Dinges | M | 48 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
| Clarence Peter | M | - |
MaxiVAX SA
MaxiVAX SA Miscellaneous Commercial ServicesCommercial Services MaxiVAX SA is a Swiss clinical stage biotechnology company. The private company is based in Geneva, Switzerland. The company was founded by Bernard Mach. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Marc Weber | M | 53 |
University of Zurich
| 7 jaar |
| Reto Suter | M | 53 |
University of Zurich
| 8 jaar |
| Judith Bischof | M | 50 |
University of Zurich
| 6 jaar |
| Rene Dittrich | M | 52 |
University of Zurich
| 6 jaar |
| Cédric Perlet | M | - |
University of Zurich
| 7 jaar |
| Teodoro D. Cocca | M | 51 |
University of Zurich
| 7 jaar |
| Marcel Kucher | M | 53 |
University of Zurich
| 4 jaar |
| Daniel Anders | M | 54 |
University of Zurich
| 2 jaar |
| Iris Bohnet Zürcher | M | 58 |
University of Zurich
| 3 jaar |
| Christian Kopfli | M | 58 |
University of Zurich
| 3 jaar |
| Martin Eisenring | M | - |
University of Zurich
| 3 jaar |
| Andreas Knecht | M | 55 |
University of Zurich
| 6 jaar |
| Oliver Hofmann | M | 53 |
University of Zurich
| 4 jaar |
| André Odermatt | M | 64 |
University of Zurich
| 4 jaar |
| Nic Dreckmann | M | 50 |
University of Zurich
| 4 jaar |
| Hans Wicki | M | 60 |
University of Zurich
| 5 jaar |
| Dimitri Papadopoulos | M | - |
University of Zurich
| 3 jaar |
| Marija Zecevic | M | 51 |
University of Zurich
| 5 jaar |
| Sven Schaltegger | M | - |
University of Zurich
| 7 jaar |
| Morten Holm Pedersen | M | - |
University of Zurich
| 2 jaar |
| Reto Schnabel | M | - |
University of Zurich
| 4 jaar |
| Thomas Gottstein | M | 60 |
University of Zurich
| 3 jaar |
| Rudolf Keller | M | - |
University of Zurich
| 7 jaar |
| Marco Probst | M | - |
University of Zurich
| 5 jaar |
| Tobias Foster | M | 49 |
University of Zurich
| 4 jaar |
| Marcel Dillier | M | - |
University of Zurich
| 5 jaar |
| Wolfgang Weber | M | 57 |
University of Zurich
| 3 jaar |
| Patrick Schildknecht | M | 52 |
University of Zurich
| 4 jaar |
| Michael Steinmann | M | 58 |
University of Zurich
| 3 jaar |
| Michael Sidler | M | 55 |
University of Zurich
| 3 jaar |
| Nicole Tschudi | F | 52 |
University of Zurich
| 5 jaar |
| Michael Altorfer | M | - |
University of Zurich
| 3 jaar |
| Patrick Frost | M | 56 |
University of Zurich
| 3 jaar |
| Chris Burger | M | - |
University of Zurich
| 6 jaar |
| Beat Buehlmann | M | 56 |
University of Zurich
| 3 jaar |
| Markus Foser | M | 55 |
University of Zurich
| 4 jaar |
| Patrik Forrer | M | - |
University of Zurich
| 3 jaar |
| Rahul Sen Gupta | M | 52 |
University of Zurich
| 1 jaar |
| Peter Lichtlen | M | 56 |
University of Zurich
| 4 jaar |
| Haleh Brönner | M | 55 |
University of Zurich
| 6 jaar |
| Marc Loeb | M | 53 |
University of Zurich
| 1 jaar |
| Giacomo Balzarini | M | 56 |
University of Zurich
| 4 jaar |
| Philippe Schenk | M | - |
University of Zurich
| 3 jaar |
| Renata Jungo Brüngger | F | 62 |
University of Zurich
| 2 jaar |
| Daniel Schmucki | M | 56 |
University of Zurich
| 1 jaar |
| Thomas Moser | M | 57 |
University of Zurich
| 3 jaar |
| Patrick Rene Stutz | M | - |
University of Zurich
| 6 jaar |
| Roger Meier-Rossi | M | - |
University of Zurich
| 3 jaar |
| Andreas Schulthess | M | 54 |
University of Zurich
| 4 jaar |
| Beat Walti | M | 55 |
University of Zurich
| 3 jaar |
| Thomas Oetterli | M | 55 |
University of Zurich
| 4 jaar |
| Nicola C. Port | F | - |
University of Zurich
| 3 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Zwitserland | 57 | 83.82% |
| Frankrijk | 11 | 16.18% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Sven Zimmermann
- Persoonlijk netwerk
